MedTrace Logo

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer

NCT03509298 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-10-19

No results posted yet for this study

Summary

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced pancreatic cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for pancreatic cancer.

Conditions

  • Advanced Pancreatic Cancer

Interventions

BIOLOGICAL

Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer

CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1

PROCEDURE

cryotherapy

the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.

Sponsors & Collaborators

  • Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

    collaborator INDUSTRY

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Jibing Chen, Doctor · Guangzhou Fuda Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-12
Primary Completion
2020-05-20
Completion
2020-07-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03509298 on ClinicalTrials.gov